RSU

Graphene Manufacturing Group ISO 9001:2015 Certification, Demonstrating Commitment to Quality Management

Retrieved on: 
Tuesday, February 20, 2024

This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.

Key Points: 
  • This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.
  • The ISO 9001 certification process involved a rigorous assessment of GMG's quality management system, covering all aspects of its operations, from customer service to production, delivery, and technical support.
  • The benefits of ISO 9001 certification for GMG include:
    - Enhanced customer satisfaction through improved product and service quality.
  • GMG is committed to maintaining its ISO 9001 certification and continuously improving its quality management system.

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Retrieved on: 
Friday, March 8, 2024

The Company is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, February 27, 2024 (the “Meeting”).

Key Points: 
  • The Company is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, February 27, 2024 (the “Meeting”).
  • Shareholders voted in favour of each resolution put forth at the Meeting.
  • “PharmAla continues to make the important choices necessary for the future of both our business, and the Psychedelic Pharmaceuticals sector more broadly,” said Jodi Butts, Board Chair, PharmAla Biotech.
  • “We are grateful that PharmAla’s shareholders have agreed with management’s recommendations on a variety of timely corporate governance matters.

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $0.99 per share, which is equal to the closing price of the Common Stock on March 4, 2024 (the “Grant Date”).
  • The RSUs will vest annually over a three-year period, with one-third of the RSUs vesting on each anniversary of the Grant Date, subject to such employee's continued employment on each vesting date.
  • The options and RSUs are subject to the terms and conditions of the 2023 Inducement Plan, and the terms and conditions of the stock option and RSU agreements covering the grants.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company.

Key Points: 
  • WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employee received 2,795 restricted stock units (RSUs).
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date.

Notice of Inducement Grants for Kurt Hoff, Lantronix Vice President, Worldwide Sales

Retrieved on: 
Monday, March 4, 2024

The RSU award is scheduled to vest over three years as follows: one-third of the award is scheduled to vest on March 1, 2025, and the remaining RSUs are scheduled to vest ratably each quarter thereafter over a period of two years.

Key Points: 
  • The RSU award is scheduled to vest over three years as follows: one-third of the award is scheduled to vest on March 1, 2025, and the remaining RSUs are scheduled to vest ratably each quarter thereafter over a period of two years.
  • The PSU award is scheduled to vest based on the company’s relative total stockholder return (TSR) over a three-year period beginning on the employment commencement date.
  • Each award is subject to the terms and conditions of the applicable award agreement.
  • The inducement RSUs and PSUs are granted as employment inducement awards in accordance with NASDAQ Listing Rule 5635(c)(4).

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024

RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
  • These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Retrieved on: 
Monday, February 26, 2024

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.

Key Points: 
  • WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.
  • “We are delighted to welcome an accomplished leader such as Pamela to Disc, where her breadth of commercial experience and acumen will be instrumental as the company continues to grow,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • Most recently, she served as the Chief Commercial Officer of Albireo, which was acquired by Ipsen, spearheading the successful launch of Bylvay for a rare cholestatic liver disease.
  • The Inducement Award was approved by Disc’s Board of Directors (the “Board”), including a majority of the independent directors serving on the Board.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 8, 2024

The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price of $14.79 per share, the closing price of Evolus’ common stock on the date of grant.
  • The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesting on each annual anniversary of the vesting commencement date.
  • The RSUs vest 25% on each annual anniversary of the vesting commencement date.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 8, 2024

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new employees in connection with their employment with UroGen.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new employees in connection with their employment with UroGen.
  • Up to 35,000 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs.
  • The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder.
  • The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
  • The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option award agreement covering the grant.